Theranostic Nanoparticles for Pancreatic Cancer Treatment

Endocr Metab Immune Disord Drug Targets. 2021;21(2):203-214. doi: 10.2174/1871530320666200516164911.

Abstract

Pancreatic cancer is one of the low vascular permeable tumors with a high mortality rate. The five-year survival period is ~5%. The field of drug delivery is at its pace in developing unique drug delivery carriers to treat high mortality rate cancers such as pancreatic cancer. Theranostic nanoparticles are the new novel delivery carriers where the carrier is loaded with both diagnostic and therapeutic agents. The present review discusses various therapeutic and theranostic nanocarriers for pancreatic cancer.

Keywords: Theranostics; chemotherapy; combinatorial treatment and 3D pancreatic cancer; imaging; magnetic hyperthermia; nanoparticles; pancreatic cancer.

Publication types

  • Review

MeSH terms

  • Animals
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
  • Antineoplastic Combined Chemotherapy Protocols / metabolism
  • Clinical Trials as Topic / methods
  • Drug Carriers / administration & dosage*
  • Drug Carriers / metabolism
  • Humans
  • Nanoparticles / administration & dosage*
  • Nanoparticles / metabolism
  • Pancreatic Neoplasms / genetics
  • Pancreatic Neoplasms / metabolism
  • Pancreatic Neoplasms / therapy*
  • Precision Medicine / methods*
  • RNA, Small Interfering / administration & dosage
  • RNA, Small Interfering / genetics

Substances

  • Drug Carriers
  • RNA, Small Interfering